Latest Breaking News On - Alexandra maclean - Page 1 : comparemela.com

Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy s Disease)

Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy s Disease)
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomGreat britainChristopher grunseichAlexandra macleanTahseen mozaffarJaclyn jaffeDrug administration or european medicines agencyNational institute of neurological disordersAnnji pharmaceutical coCompany phaseFortress biotech incUniversity of californiaLasker clinical research scholarLaboratory medicineEuropean union

Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesAlexandra macleanChristopher grunseichJaclyn jaffeTahseen mozaffarNeuromuscular centerLasker clinical research scholarDrug development researchNational institute of neurological disordersFortress biotech incAvenue therapeutics incLaboratory medicineAmerican society for experimental neurotherapeuticsDivision of neuromuscular diseasesUniversity of californiaChief executive officer

Avenue Therapeutics (ATXI) Reports Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101

Avenue Therapeutics (ATXI) Reports Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Alexandra macleanAvenue therapeutics incDrug development researchAvenue therapeuticsGenetic absence epilepsy ratsChief executive officer

Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy

Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesAlexandra macleanJaclyn jaffeFortress biotech incAvenue therapeutics incDrug development researchTherapeutics announces publicationTranslational modelGenetic absence epilepsy ratsChief executive officerFortress biotechPrivate securities litigation reform act

Lindsay RosenwaldÃ¢€™s Fortress Bio (NASDAQ: FBIO) Spotlight on 2024 Milestones from Subsidiaries -February 02, 2024 at 02:42 pm EST

New York, Feb 2, 2024 - Fortress Biotech , a unique biotech company led by industry veteran Dr. Lindsay Rosenwald, focused on identifying, in-licensing and developing high-potential marketed drugs.

New yorkUnited statesLindsay rosenwaldAlexandra macleanBryan feinbergClaude maraouiJourney medical corporationJourney medical corporation submitsDrug administrationPlato dataFortress bioTherapeutics finalizes phaseNew drug applicationJourney medicalAvenue therapeutics